• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.

作者信息

Kriegsmann Katharina, Manta Calin, Schwab Ricarda, Mai Elias K, Raab Marc S, Salwender Hans J, Fenk Roland, Besemer Britta, Dürig Jan, Schroers Roland, von Metzler Ivana, Hänel Mathias, Mann Christoph, Asemissen Anne M, Heilmeier Bernhard, Bertsch Uta, Huhn Stefanie, Müller-Tidow Carsten, Goldschmidt Hartmut, Hundemer Michael

机构信息

Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.

出版信息

Blood Adv. 2023 Feb 14;7(3):379-383. doi: 10.1182/bloodadvances.2022008005.

DOI:10.1182/bloodadvances.2022008005
PMID:35914229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9898596/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/360a/9898596/cd07a18e53be/BLOODA_ADV-2022-008005-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/360a/9898596/cd07a18e53be/BLOODA_ADV-2022-008005-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/360a/9898596/cd07a18e53be/BLOODA_ADV-2022-008005-gr1.jpg

相似文献

1
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.NGF对多发性骨髓瘤患者骨髓和外周血异常浆细胞评估的比较
Blood Adv. 2023 Feb 14;7(3):379-383. doi: 10.1182/bloodadvances.2022008005.
2
[A study on bone marrow plasma cell morphology in different electrophoretic blood protein findings in 50 cases of myelomatosis].
Nord Med. 1956 Mar 15;55(11):369-70.
3
The reticulo-endothelial origin of the bone marrow plasma cells in hypersensitive states.过敏状态下骨髓浆细胞的网状内皮起源。
J Lab Clin Med. 1947 Jun;32(6):749-55.
4
[Phosphor uptake of plasmocytoma cells and normal bone marrow cells in vitro].[浆细胞瘤细胞与正常骨髓细胞在体外的磷摄取]
Klin Wochenschr. 1956 Feb 1;34(5-6):157-60. doi: 10.1007/BF01480306.
5
[Nuclear inclusions in normally differentiated bone marrow plasma cells].[正常分化的骨髓浆细胞中的核内包涵体]
Blut. 1962 Mar;8:34-6. doi: 10.1007/BF01570370.
6
[The normal plasma cells of bone marrow].[骨髓中的正常浆细胞]
Internist Prax. 1965;5(3):385-9.
7
Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals.骨髓浆细胞是慢性感染个体血清中HIV-1特异性抗体的主要来源。
J Immunol. 2015 Mar 15;194(6):2561-8. doi: 10.4049/jimmunol.1402424. Epub 2015 Feb 13.
8
Plasma cells in bone marrow.骨髓中的浆细胞。
N Engl J Med. 1969 Mar 27;280(13):729.
9
Plasma cells in bone marrow.骨髓中的浆细胞。
N Engl J Med. 1969 Mar 27;280(13):729.
10
Plasma cells in bone marrow.骨髓中的浆细胞。
N Engl J Med. 1969 Mar 27;280(13):729.

本文引用的文献

1
Minimal residual disease negativity by next-generation flow in non-CR myeloma patients.非完全缓解骨髓瘤患者通过下一代流式细胞术检测达到微小残留病阴性。
EJHaem. 2020 Sep 22;1(2):563-566. doi: 10.1002/jha2.103. eCollection 2020 Nov.
2
Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.多发性骨髓瘤患者的微小残留病评估：影响重大的微小疾病
Front Oncol. 2022 Jan 26;11:801851. doi: 10.3389/fonc.2021.801851. eCollection 2021.
3
Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells.
基于游离 DNA 和循环浆细胞监测外周血中的多发性骨髓瘤。
Ann Hematol. 2022 Apr;101(4):811-824. doi: 10.1007/s00277-022-04771-5. Epub 2022 Feb 1.
4
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.一项大型荟萃分析确立了 MRD 阴性在多发性骨髓瘤患者长期生存结局中的作用。
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
5
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.采用新一代流式细胞术对多发性骨髓瘤治疗后循环肿瘤浆细胞进行血液监测。
Blood. 2019 Dec 12;134(24):2218-2222. doi: 10.1182/blood.2019002610.
6
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).基于循环肿瘤血浆细胞（CTPC）的初诊 MGUS 和多发性骨髓瘤微创血液特征分析的下一代流程。
Blood Cancer J. 2018 Nov 19;8(12):117. doi: 10.1038/s41408-018-0153-9.
7
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.采用深度测序技术从循环肿瘤 DNA 检测多发性骨髓瘤微小残留病灶与骨髓检测结果不相关。
Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197.
8
Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.自体干细胞采集时的外周血流微小残留病状态可预测多发性骨髓瘤的预后。
Bone Marrow Transplant. 2018 Dec;53(12):1599-1602. doi: 10.1038/s41409-018-0245-y. Epub 2018 Jun 8.
9
Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.全面描绘微小残留病灶中循环和骨髓衍生多发性骨髓瘤细胞的特征。
Semin Hematol. 2018 Jan;55(1):33-37. doi: 10.1053/j.seminhematol.2018.02.010. Epub 2018 Mar 1.
10
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.多发性骨髓瘤患者自体 PBSC 采集时的循环浆细胞是一个负预后因素，即使在移植后维持治疗时代也是如此。
Biol Blood Marrow Transplant. 2018 Jul;24(7):1386-1391. doi: 10.1016/j.bbmt.2018.02.017. Epub 2018 Mar 1.